Novo Nordisk nelle notizie
Soluzioni sanitarie per il diabete
Tamtam ha trovato 20 articoli recenti su Novo Nordisk.
- UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
- Novo Nordisk loses another patent behind Ozempic and Wegovy drugs
- Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
- Novo skifter ud i topledelsen
- Your Ozempic Prescription May Come With a Surprising Bonus: Slower Aging
- Novo Nordisk stock target cut at Citi on lack of margin growth
- Aktien er nede med 22 pct. i år: Her er analytikernes dom over Novo-aktien
- Novo Nordisk introduces new diabetes treatment option in Thailand
- Hackers had access to Novo Nordisk systems for at least 47 days
- Novo goes on deal spree amid semaglutide patent expiries
- QMs samarbejde med Novo Nordisk og Qpurpose
- Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
- Is Novo Nordisk (CPSE:NOVO B) Still Reasonable After New Semaglutide Data?
- Novo Stock Is Down More Than 70% From Its Peak. Value Trap or Generational Buying Opportunity?
- Novo Nordisk Probes Patient Priorities in German Hemophilia A Study
- Novo Nordisk (NVO) Pulls Back Sharply, Is It A Bargain?
- Novo flags FDA hemophilia review extension tied to manufacturing site corrections
- FDA delays decision on Novo's hemophilia drug
- Novo Nordisk A/S – Share repurchase programme
- Novo Nordisk A/S : JP Morgan is Neutral
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Novo Nordisk?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili